Online citations, reference lists, and bibliographies.

Proton-pump Inhibitor Use And Fracture Risk: An Updated Systematic Review And Meta-analysis

Yousef Nassar, Seth J. Richter
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Background This study's objective was to evaluate the association between proton-pump inhibitor (PPI) use and bone fracture incidence and bone mineral density (BMD) by meta-analyzing the estimates reported by epidemiological and cohort studies. Methods Data were acquired from studies identified after a literature search in electronic databases. Odds ratios (ORs), hazard ratios (HRs), and risk ratios (RRs) between PPI use and bone fracture incidence were pooled under the random effects model, and meta-analysis of standardized mean differences between PPI users and controls in cross-sectional values and BMD changes was conducted. Results Thirty-three studies fulfilled the eligibility criteria. These studies provided data from 2,714,502 individuals with a mean age of 66.91 years (95% confidence interval [CI], 63.37–70.46); 33.21% (95% CI, 30.44–35.99) were males and 64.61% (95% CI, 60.73–68.49) were females. Overall, fracture incidence was 22.04% (95% CI, 16.10–27.97) in PPI users and 15.57% (95% CI, 12.28–18.86) in controls. The overall effect size of the point estimate was 1.28 (95% CI, 1.22–1.35) between PPI use and bone fracture incidence. There was a trend towards increased fracture incidence from short duration use: OR 1.29 (95% CI, 1.19–1.40), medium duration use: OR 1.33 (95% CI, 1.12–1.55) and long duration use: OR 1.62 (95% CI, 1.33–1.90). There was no significant difference in the standardized mean differences between PPI users and controls, either in cross-sectional BMD values or in the BMD change observed in longitudinal studies. Conclusions Pooling of ORs, HRs, and RRs suggested that PPI use might increase fracture risk. However, there was no effect of PPI use on BMD.
This paper references
10.1503/cmaj.071330
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
10.1002/jbmr.1714
Hip fracture and risk of acute myocardial infarction: a nationwide study.
Chia-Hung Chiang (2013)
10.1007/s00198-016-3509-7
Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?
Toshihiro Sugiyama (2016)
10.1503/cmaj.080873
Proton pump inhibitors: balancing the benefits and potential fracture risks
J. Brent Richards (2008)
10.1161/STROKEAHA.117.019166
Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis
Konark Malhotra (2018)
10.1007/s00198-017-4262-2
Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study
S. Lin (2017)
10.1056/NEJMoa1007964
Clopidogrel with or without omeprazole in coronary artery disease.
Deepak L. Bhatt (2010)
Use of proton pump inhibitors is associated with lower trabecular
M Maggio
10.1111/apt.14345
Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population‐based nested case‐control study
S Kumar (2017)
10.1111/1756-185X.12866
Proton pump inhibitors use and change in bone mineral density.
Abbas Arj (2016)
10.1038/ajg.2009.115
Guidelines for Prevention of NSAID-Related Ulcer Complications
Frank L. Lanza (2009)
10.1007/s00535-012-0722-9
A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate
Joongyub Lee (2012)
10.1053/j.gastro.2010.03.055
Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
Douglas A. Corley (2010)
10.1002/jbmr.2279
Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.
Joshua R. Lewis (2014)
10.1111/febs.12478
Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity.
João Costa-Rodrigues (2013)
10.1016/j.hlc.2017.10.020
Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review.
Timothy P Shiraev (2018)
10.1002/jbmr.2344
Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.
Daniel H. Solomon (2015)
10.1007/s00774-015-0699-6
Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors
Elton Bahtiri (2015)
10.1007/s00198-012-2112-9
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study
L-A. Fraser (2012)
10.1001/archinte.166.2.241
Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2.
B. Gage (2006)
10.1136/bmj.38643.663843.55
Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study
John W. Roche (2005)
10.1056/NEJM198812293192605
The physiology of gastric acid secretion.
M. Michael Wolfe (1988)
10.1002/pds.1972
Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.
Bernie McGowan (2010)
10.1016/j.bone.2013.09.014
Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
Marcello Maggio (2013)
10.1097/MNH.0000000000000406
The association of proton pump inhibitors and chronic kidney disease: cause or confounding?
Tingting Li (2018)
3 . 141 pump inhibitor use and risk of hip fracture in kidney transplant recipients
Lewis
10.1016/j.annepidem.2014.01.004
Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.
A L Adams (2014)
10.1007/s00198-015-3365-x
Proton-pump inhibitors and risk of fractures: an update meta-analysis
Bangjian Zhou (2015)
10.4137/CGast.S9588
Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?
Cheryl R Durand (2012)
10.1001/archinternmed.2011.20
Proton pump inhibitor use and the antifracture efficacy of alendronate.
B. Abrahamsen (2011)
10.1136/bmj.d2238
Levothyroxine dose and risk of fractures in older adults: nested case-control study
Marci R Turner (2011)
10.1038/ajg.2011.113
Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies
S. Ngamruengphong (2011)
10.1001/jama.2009.261
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
P. Ho (2009)
10.1016/j.maturitas.2014.05.019
Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
L Moberg (2014)
10.1592/phco.28.8.951
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
James A Kaye (2008)
10.1001/jama.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
Proton Yousef Nassar, et al. 150 http://e-jbm.org/ https://doi.org/10.11005/jbm.2018.25.3.141 pump inhibitor use and risk of hip fracture in kidney transplant recipients
CR Lenihan (2017)
Risk factors, preoperative assessment, and postoperative management
T S Dharmarajan (2006)
10.1053/j.ajkd.2016.09.019
Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients.
Colin R. Lenihan (2017)
10.1038/ajg.2016.584
Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients
Jan Zirk-Sadowski (2017)
pump inhibitor use and risk of hip fracture in kidney transplant recipients
(2017)
10.1016/j.bone.2012.09.028
Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.
C. Reyes (2013)
10.1053/j.gastro.2009.11.014
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
L. Targownik (2010)
10.1007/s00223-014-9855-6
The Relationship Between Proton Pump Inhibitor Adherence and Fracture Risk in the Elderly
Jian Ding (2014)
10.1002/pds.2026
Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.
H C Chiu (2010)
10.1007/s00198-010-1337-8
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
Sander Pouwels (2010)
10.1177/2151458512463392
The Impact of Comorbidity on Perioperative Outcomes of Hip Fractures in a Geriatric Fracture Model
Isaura B Menzies (2012)
10.1097/MOG.0b013e328358d5b9
Proton pump inhibitors: potential adverse effects
Neena S Abraham (2012)
10.1007/s00198-011-1574-5
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors
Christian Roux (2011)
Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women
LM Moberg (2014)
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos)
LE Targownik (2012)
10.1186/s12877-016-0383-2
Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
Anna-Maija Tolppanen (2016)
Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad
C de la Coba Ortiz (2016)
10.2174/156720109787846225
Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo.
Aly R. Sheraly (2009)
Proton-pump inhibitor use and hip fractures in men: a population-based casecontrol study
AL Adams (2014)
Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.
B. Farrell (2017)
10.1038/ajg.2012.200
The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos)
L. Targownik (2012)
10.1007/s00296-013-2709-0
Bone density in proton pump inhibitors users: a prospective study
K. Ozdil (2013)
10.1136/bmj.e372
Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study
H. Khalili (2012)
10.1001/archinternmed.2010.94
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
S. Gray (2010)
10.17235/reed.2016.4232/2016
Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva.
Cristóbal de la Coba Ortiz (2016)
10.1016/j.bone.2015.08.024
The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
Mariëlle M C van der Hoorn (2015)
Use of proton pump inhibitors increased the risk of hip fracture: a populationbased case-control study
HF Chiu (2010)
Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data. Bone 2013;57:269-71
B Abrahamsen (2013)
10.1177/2042098613482484
Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications
Joel J. Heidelbaugh (2013)
10.3810/pgm.2006.06.1638
Hip fracture
T. S. Dharmarajan (2006)
10.1007/s00223-006-0021-7
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
P. Vestergaard (2006)
Proton pump inhibitor use in hospitalized patients: is overutilization becoming a problem? Clin Med Insights Gastroenterol 2012;5:65-76
C Durand (2012)
density in older individuals
LM Moberg (2013)
10.1016/j.bone.2013.08.013
Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
Bo Abrahamsen (2013)
10.1038/ajg.2016.481
Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure
L. Targownik (2017)
10.1016/j.maturitas.2009.07.006
Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
Marc R Fournier (2009)
10.1111/jgh.13737
Proton pump inhibitors: Risks of long‐term use
Leonardo Henry Eusebi (2017)
10.1007/s00198-015-3168-0
Use of proton pump inhibitors is associated with fractures in young adults: a population-based study
Daniel E Freedberg (2015)
Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 2013;57:437-42
M Maggio (2013)
10.1007/s40256-016-0160-9
How May Proton Pump Inhibitors Impair Cardiovascular Health?
Roman A. Sukhovershin (2016)
10.1038/ajg.2009.48
Proton Pump Inhibitors and Bone Fractures?
Loren Laine (2009)
10.1016/S1568-1637(02)00045-4
Hip fractures among the elderly: causes, consequences and control
R. Marks (2003)



This paper is referenced by
10.1007/164_2019_340
Drugs Causing Bone Loss.
Peter Vestergaard (2019)
10.1080/1744666X.2019.1705784
Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies
Alfredo J Lucendo (2019)
10.1007/s40259-020-00427-w
Targeted Therapies for Eosinophilic Gastrointestinal Disorders
Alfredo J. Lucendo (2020)
10.24304/kjcp.2019.29.3.147
Association of Proton Pump Inhibitor Use and Risk of Fracture Based on the National Health Insurance Sample Cohort Database (2002~2013)
Jong Joo Kim (2019)
10.3389/fendo.2020.00473
Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?
Yohannes T. Ghebre (2020)
Top 10 Self Learning articles from 2017.
Samantha Moe (2019)
10.1002/9781119513636.ch5
The Effects of TADs on the Alveolar Bone
Jen-Yin Chen (2020)
10.1111/nep.13681
Hospitalised fracture rates amongst patients with chronic kidney disease in Australia using data linkage.
R. Lin (2019)
10.1183/2312508X.10024418
Evaluation and management of severe asthma in children
Mehtap Haktanir Abul (2019)
10.2147/DDDT.S260565
Effects of Calcium and Annatto Tocotrienol Supplementation on Bone Loss Induced by Pantoprazole in Male Rats
K. Chin (2020)
10.3390/ijerph16152777
Association between Peptic Ulcer Disease and Osteoporosis: The Population-Based Longitudinal Cohort Study in Korea
Phill Hoon Yoon (2019)
10.1016/j.lfs.2018.12.058
Proton pump inhibitors therapy and risk of bone diseases: An update meta‐analysis
J. Liu (2019)
10.1053/j.gastro.2019.05.056
Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
P. Moayyedi (2019)
Semantic Scholar Logo Some data provided by SemanticScholar